Enhancing Capital’s AbbVie ABBV Stock Holding History

Enhancing Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$503K	Hold	2,000	–	–	0.35%	60
2026 Q1	$435K	Hold	2,000	–	–	0.32%	62
2025 Q4	$457K	Hold	2,000	–	–	0.33%	63
2025 Q3	$463K	Hold	2,000	–	–	0.34%	66
2025 Q2	$371K	Hold	2,000	–	–	0.28%	75
2025 Q1	$419K	Hold	2,000	–	–	0.34%	72
2024 Q4	$355K	Buy	+2,000	New	+$368K	0.28%	75
2022 Q3	$278K	Hold	2,000	–	–	0.34%	64
2022 Q2	$306K	Hold	2,000	–	–	0.37%	61
2022 Q1	$324K	Hold	2,000	–	–	0.35%	64
2021 Q4	$271K	Buy	+2,000	New	+$236K	0.29%	69

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Enhancing Capital's ABBV Position: Q2 2026 in Review

Enhancing Capital held its AbbVie (ABBV) position steady in Q2 2026 at 2,000 shares worth $503K. The position accounts for 0.35% of the portfolio, ranked #60.

Enhancing Capital first reported a position in ABBV in Q4 2021 and has held it in 11 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Enhancing Capital held 2,000 shares of AbbVie worth $503K as of Q2 2026.
Enhancing Capital left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.35% of Enhancing Capital's portfolio in Q2 2026, its #60 holding.
Enhancing Capital first reported a position in AbbVie in Q4 2021 and has held it in 11 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Enhancing Capital's 13F filing for Q2 2026, filed 11 Aug 2026.